Industry / United States
FDA Rejects Schering-Plough's Bridion
August 2008 | Company News AlertThe US FDA has issued a "not-approvable" letter for Schering-Plough's Bridion (sugammadex), a drug used to reverse the effects of anesthesia.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
